Reconnecting

The current page stays visible while onset.to reconnects in the background.

Beckley’s 5-MeO-DMT Phase 2b shows rapid, durable antidepressant effects in treatment-resistant depression

Open original

5‑MeO‑DMT in Beckley Psytech’s intranasal program (BPL-003) produced rapid and durable antidepressant effects in a Phase 2b study for treatment-resistant depression. In the study, participants receiving higher doses plus psychological support showed large MADRS score reductions by day 29, including a reported mean decrease of 11.1 points for 12 mg versus 5.8 in the 0.3 mg comparator group. The mid-dose group (8 mg) was also reported to perform slightly better, and the antidepressant effect was described as largely maintained through day 57. Safety results were presented as generally well-tolerated across doses, with no drug-related serious adverse events and no instances of treatment-emergent suicidal intent or behaviour in the mid- and high-dose arms. The piece also compares Beckley’s topline readout to GH Research’s concurrently developed inhaled 5‑MeO‑DMT approach and highlights differences in trial design, endpoints, and dosing models that may affect interpretation.